4
Changes in Ownership
Atea Pharmaceuticals, Inc. Filed Acc 0000950170-25-013853
Chief Development Officer gave up 14,134 shares (to pay taxes)
- Chief Development Officer acquired 11,250 shares (grant or award)
- Chief Development Officer acquired 46,800 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hammond Janet MJ Chief Development Officer | 2025-01-31 | Option exercise | +46,800 | 84,272 | D | ||
| Hammond Janet MJ Chief Development Officer | 2025-01-31 | Grant or award | +11,250 | 95,522 | D | ||
| Hammond Janet MJ Chief Development Officer | 2025-01-31 | Shares withheld for taxes | −14,134 | $3.06 | $43,250 | 81,388 | D |
| Derivatives | |||||||
| Hammond Janet MJ Chief Development Officer | 2025-01-31 | Option exercise · Restricted Stock Units | −46,800 | 46,800 | D | ||
| Hammond Janet MJ Chief Development Officer | 2025-01-31 | Grant or award · Restricted Stock Units | +11,250 | 11,250 | D | ||
| Hammond Janet MJ Chief Development Officer | 2025-01-31 | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | D | ||
Loading xslF345X05/ownership.xml…